From earlier posts it seems clear that PRR has the global commercialization rights for CVac. That's the good news for CVac. But going back to my earlier question about patents and their scope, can anyone confirm whether PRR's patents mean that only PRR can commercialize drugs that target Mucin-1 ?
I strongly suspect not else why would Oncothyreon be developing Stimuvax (under license to Merck) which specifically targets MUC-1 (albeit that they are focusing on lung cancer at present instead of ovarian cancer).
I'm just wondering to what extent Oncothyreon/Merck may expect to compete with the likes of Prima and Dendreon. Who else is in this game ?
http://www.oncothyreon.com/clinical/stimuvax.html
stimuvax phase iii (biomira, now oncothyreon)
-
- There are more pages in this discussion • 24 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
33.5¢ |
Change
0.025(8.06%) |
Mkt cap ! $486.6M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 34.8¢ | 31.3¢ | $1.379M | 4.179M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 170360 | 33.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 34.0¢ | 115131 | 3 |
View Market Depth
| Last trade - 16.10pm 14/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |